Free Trial

DaVita Inc. (NYSE:DVA) Stock Holdings Increased by Advisors Asset Management Inc.

DaVita logo with Medical background
Remove Ads

Advisors Asset Management Inc. increased its position in DaVita Inc. (NYSE:DVA - Free Report) by 24.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 22,686 shares of the company's stock after purchasing an additional 4,485 shares during the quarter. Advisors Asset Management Inc.'s holdings in DaVita were worth $3,393,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in DVA. SBI Securities Co. Ltd. acquired a new position in shares of DaVita in the fourth quarter worth about $41,000. Quarry LP acquired a new stake in DaVita in the third quarter valued at $60,000. Venturi Wealth Management LLC boosted its stake in DaVita by 59.8% during the 4th quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock valued at $61,000 after acquiring an additional 152 shares during the last quarter. Versant Capital Management Inc grew its holdings in DaVita by 58.7% during the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company's stock worth $68,000 after acquiring an additional 169 shares in the last quarter. Finally, Blue Trust Inc. increased its position in shares of DaVita by 39.7% in the 4th quarter. Blue Trust Inc. now owns 461 shares of the company's stock worth $76,000 after purchasing an additional 131 shares during the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Stock Performance

Shares of NYSE DVA traded up $0.19 during mid-day trading on Tuesday, hitting $150.60. The company had a trading volume of 662,216 shares, compared to its average volume of 783,786. DaVita Inc. has a 12 month low of $125.64 and a 12 month high of $179.60. The stock has a market cap of $12.05 billion, a price-to-earnings ratio of 14.02, a PEG ratio of 1.07 and a beta of 0.99. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The firm's 50 day simple moving average is $158.40 and its two-hundred day simple moving average is $157.57.

Remove Ads

DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, equities research analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on DVA. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a research report on Friday, February 21st. Barclays lifted their target price on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 18th. StockNews.com downgraded DaVita from a "buy" rating to a "hold" rating in a report on Friday. Finally, Cowen restated a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $166.33.

Read Our Latest Stock Analysis on DVA

DaVita Profile

(Free Report)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Featured Stories

Institutional Ownership by Quarter for DaVita (NYSE:DVA)

Should You Invest $1,000 in DaVita Right Now?

Before you consider DaVita, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.

While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

3 Stocks to Buy on the Dip—and 3 to Dump Fast
Trump Tariffs Tumble the Stock Market—Here’s How to Protect Your Money
Donald Trump Owns These 7 Stocks, Should You?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads